Common Polymorphisms in the NFKBIA Gene and Cancer Susceptibility: A Meta-Analysis

AB 1 Meng Zhang*
EF 2 Junjie Huang*
B 1 Xiuxiu Tan*
D 1 Jian Bai
BC 1 Hao Wang
DE 1 Yukun Ge
CD 1 Hu Xiong
BE 3 Jizhou Shi
CD 1 Wei Lu
BEG 1 Zhaojie Lv
BCDE 4,5 Chaozhao Liang

* These authors contributed equally to the work

Corresponding Authors: Chaozhao Liang, e-mail: liang_chaozhao@163.com; Zhaojie Lv, e-mail: 794225924@qq.com

Source of support: The work by C.L. and Z.L. was supported by Shenzhen Health and Family Planning Key Discipline Promotion Project (No. 201506026)

Background: NFKBIA encodes the inhibitors of nuclear factor-kB (NF-kB), which regulate the translation of the genes involved in the inflammatory and immune reactions. Polymorphisms (rs2233406, rs3138053, and rs696) of NFKBIA have been implicated in susceptibility to many cancer types.

Material/Methods: To evaluate the association between polymorphisms of NFKBIA and cancer susceptibility, a meta-analysis including a total of 7182 cancer cases and 10 057 controls from 28 case-control studies was performed. Data were extracted and pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated.

Results: Combined data demonstrated that rs3138053 polymorphism of NFKBIA was associated with cancer susceptibility in an allelic model (C vs. T: OR=10.754, 95%CI=4.175–27.697, \(P_{\text{heterogeneity}}=0.000\)), while the polymorphism of rs696 appeared to play a protective role in tumorigenesis (CC+CT vs. TT: OR=0.879, 95%CI=0.787–0.982, \(P_{\text{heterogeneity}}=0.107\)).

When stratification analysis was performed by cancer type, an increased association of rs3138053 was recognized in hepatocarcinoma (C vs. T: OR=42.180, 95%CI=27.970–63.612, \(P_{\text{heterogeneity}}=0.007\)), while a decreased association of rs696 was identified in Hodgkin lymphoma (C vs. T: OR=0.792, 95%CI=0.656–0.956, \(P_{\text{heterogeneity}}=0.116\); CC vs. TT: OR=0.658, 95%CI=0.448–0.965, \(P_{\text{heterogeneity}}=0.076\); CC vs. CT+TT: OR=0.734, 95%CI=0.562–0.958, \(P_{\text{heterogeneity}}=0.347\)). By ethnicity, rs696 appears to be a protective candidate among Caucasians (CT vs. TT: OR=0.809, 95%CI=0.676–0.969, \(P_{\text{heterogeneity}}=0.459\)).

Conclusions: Our data demonstrated that the rs3138053 polymorphism of NFKBIA gene is a candidate for susceptibility to overall cancers, while rs696 plays a protective role.

MeSH Keywords: Genetic Linkage • Medical Oncology • Meta-Analysis

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/895257
Background

Nuclear factor-κB (NF-κB) belongs to a family of transcription factors that play a crucial role in inflammatory and immune reactions [2]. The malfunctioning of NF-κB contributes to the inhibition of apoptosis, cell replication, and angiogenesis, all of which are occur in cancer cells [3]. Several pieces of evidence have demonstrated the connection between the defective function of IkB and cancer progression. Overexpression of NF-κB has been identified in several categories of cancer, including Hodgkin’s lymphoma, multiple myeloma, colorectal cancer, and melanoma [1]. Additionally, it was discovered that the expression of IkB is decreased among prostate cancer patients [4]. These results indicate the significant role of IkBs in regulating the oncogenic potential of NF-κB and in cancer development. From these points of view, malfunctioning in the expression of IkB may remain a risk factor for cancer.

IkBα is encoded by NFKBIA genes located on chromosome 14q13. NFKBIA rs2233406, rs3138053, and rs696 polymorphisms are situated in the binding regions for CCAAT/enhancer binding protein and GATA binding protein 2, respectively. They may regulate IkBα expression and influence NF-κB activation; these polymorphisms (rs2233406, rs3138053, and rs696) are directly related to apoptosis, inappropriate immune cell development, and delayed cell growth [5]. The effect of polymorphisms within the NFKBIA gene on cancer susceptibility has been investigated in a number of cancers [6–12]. It was reported that polymorphic variants in the 39-untranslated region of NFKBIA was associated with a susceptibility to multiple myeloma, Hodgkin’s lymphoma, prostate cancer, breast cancer, colorectal cancer, gastric cancer, and melanoma [13–19]. However, the susceptibility modulation impacts of the polymorphisms were inconsistent in various studies because the sample sizes enrolled were limited and the ethnic backgrounds of subjects in various studies were different. Evidence of the relationship between genetic polymorphisms and cancer susceptibility can be provided by a quantitative synthesis to accumulate data from different studies. In this paper we present the results of a comprehensive meta-analysis performed on publicly available databases.

Material and Methods

Literature sources and search strategy

We conducted a systematic literature search in Google Scholar, PubMed, and Web of Science databases (up to 20 June 2015) to accumulate all available studies on the association between polymorphisms of NFKBIA (rs2233406, rs3138053, and rs696) and cancer susceptibility by using the following search strategy: (“NFKBIA” OR “Nuclear factor kappa B inhibitor”) AND (“polymorphism” OR “mutation” OR “variation”) AND (“susceptibility” OR “risk” OR “effects”) AND (“cancer” OR “tumour” OR “carcinoma”). Studies were also searched manually on the reference lists of reviews and retrieved studies for additional eligible studies.

Inclusion and exclusion criteria

The articles enrolled in the present meta-analysis were consistent with these criteria: (a) the relationship between the polymorphisms in NFKBIA and cancer susceptibility was identified in the studies; (b) the study method was case-control; and (c) we could extract the ORs with 95%CIs of all the cases and controls. Studies were excluded when they were: (a) studies without sufficient raw data to evaluate odds ratios with 95% confidence intervals; (b) case-only studies; (c) duplicated publications; and (d) studies based on animals or families.

Data extraction

The data were extracted independently by 3 investigators (M. Zhang, J. J. Huang, and X. X. Tan). Data with discrepancies were discussed by all authors. The following data were collected: name of first author, publication year, country of origin, ethnicity, cancer type, total numbers of cases and controls, source of controls, and genotype or allele distribution in cases and controls. Ethnic backgrounds were categorized as Asian and Caucasian.

Statistical analysis

We assessed the relationship between the NFKBIA polymorphisms and cancer susceptibility by employing the ORs and 95%CIs in the studies and calculated the pooled ORs on the allele contrast (T vs. Tt, dominant (Tt+tt vs. TT), and recessive (tt vs. Tt+TT) models. Comparisons were also performed in heterozygote (Tt vs. TT) and homozygote (tt vs. TT) (TT, homozygotes for the common allele; Tt, heterozygotes; tt, homozygotes for the rare allele). The P values of HWE were calculated by χ² test for the genotype distribution in controls. The meta-analyses were conducted by using STATA 12.0 software (Stata Corporation, College Station, Texas). A chi-square based Q-statistic test was performed to evaluate the heterogeneity of studies in the case-control studies [20]. If the Q test (P>0.1) indicated homogeneity within studies, the fixed-effects model was used [21]; otherwise, the random-effects model was used [22]. We also evaluated heterogeneity across studies by calculation of the inconsistency index (I²<25%: no heterogeneity; I²=25–50%: moderate heterogeneity; I²>50%: significant heterogeneity). Stratification analyses were performed by source of control, cancer type, and ethnicity. We removed a single study each time to evaluate the stability of
the results. Begg’s funnel plot and Egger’s test were used to assess publication bias.

**Results**

**The identification and characteristics of eligible studies**

As demonstrated in Figure 1, after a systematic literature search in the databases on the relevance between *NFKBIA* polymorphisms and cancer susceptibility, a total of 107 potential records were initially identified. After checking the abstracts, 70 irrelevant studies were excluded, some studies were with insufficient data and others were duplicated studies. When the full texts were examined, we excluded 19 articles with no polymorphism studies, non-case-control studies, studies not on cancer, and reviews. Another 4 publications were excluded because they were on other polymorphisms in *NFKBIA*, were duplicates, or lacked eligible samples. Finally, 14 articles containing 28 independent case-control studies with a total of 7182 cases and 10 057 controls were enrolled in this meta-analysis [23–36]. Table 1 presents the characteristics of all eligible studies; 9 were population-based and the others were hospital-based. All studies were case-controlled, including 9 liver cancer studies, 5 colorectal cancer studies, 3 breast cancer studies, 3 prostate cancer studies, 2 oral cancer studies, 2 oesophageal cancer studies, 1 ovarian cancer study, and 1 multiple myeloma study. The ethnicities in these case-control studies were categorized as Asian (23 studies) and Caucasian (5 studies).

**Pooled analysis**

The primary results of the present meta-analysis and the heterogeneity test are summarized in Table 2. In addition, we also rated the methodological quality of the included studies according to the Newcastle-Ottawa Scale (Table 3). By pooling ORs and 95% CIs, we discovered that rs2233406 polymorphism of *NFKBIA* was not associated with susceptibility to cancers (Table 2A). However, we identified a significant increased susceptibility in the rs3138053 polymorphism of *NFKBIA* (C vs. T: OR=10.754, 95%CI=4.175–27.697, *P* heterogeneity=0.000; Figure 2A, Table 2B). Another impressive finding was that the polymorphism of rs696 appeared to play a protective role in tumorigenesis, as suggested by the pooled ORs (CC+CT vs. TT: OR=0.879, 95%CI=0.787–0.982, *P* heterogeneity=0.107; Figure 2B, Table 2C).

**Subgroup analysis**

In the subgroup meta-analysis by cancer type, the rs3138053 polymorphism of *NFKBIA* was revealed to be an important factor in HCC cancer susceptibility, and the pooled results were statistically significant (C vs. T: OR=42.180, 95%CI=27.970–63.612, *P* heterogeneity=0.007; Table 2B). Some significantly decreased susceptibility of the rs696 polymorphism of *NFKBIA* was observed in Hodgkin lymphoma (C vs. T: OR=0.792, 95%CI=0.656–0.956, *P* heterogeneity=0.116; CC vs. TT: OR=0.658, 95%CI=0.448–0.965, *P* heterogeneity=0.076; CC vs. CT+TT: OR=0.734, 95%CI=0.562–0.958, *P* heterogeneity=0.347; Table 2C). The source analysis indicated positive association of the rs3138053 polymorphism in the hospital-based group (C vs. T: OR=10.381, 95%CI=3.513–32.677, *P* heterogeneity=0.000; CC+CT vs. TT: OR=1.405, 95%CI=1.146–1.721, *P* heterogeneity=0.114; CC vs. TC+TT: OR=2.460, 95%CI=1.686–3.590, *P* heterogeneity=0.867; Table 2B) and the population-based group (C vs. T: OR=11.377, 95%CI=1.472–87.963, *P* heterogeneity=0.000; Table 2B). Caucasians seems to benefit more from the polymorphism of rs696 (CT vs. TT: OR=0.809, 95%CI=0.676–0.969, *P* heterogeneity=0.459; Table 2C) than Asians (CT vs. TT: OR=0.921, 95%CI=0.691–1.227, *P* heterogeneity=0.015; Table 2C).

**Figure 1.** Flow chart presenting the study selection procedure.
Table 1. Characteristics of the enrolled studies.

| SNP    | First author  | Year | Ethnicity | Genotyping method | Source of control | Cancer type | Control | \( P \) (HWE) | Case |
|--------|---------------|------|-----------|-------------------|-------------------|-------------|---------|-------------|------|
| rs2233406 | Lu et al. | 2015 | Asian | PCR-RFLP | HB | OC | 478 | 190 | 19 | 0.982 | Y | 486 | 181 | 20 |
|         | Zhang et al.  | 2014 | Asian | PCR    | HB | HCC | 1292 | 321 | 28 | 0.123 | Y | 204 | 41 | 6 |
|         | Cheng et al.  | 2013 | Asian | PCR    | HB | HCC | 438 | 78 | 4 | 0.797 | Y | 106 | 27 | 2 |
|         | Lin et al.    | 2012 | Asian | TaqMan | HB | ORC | 438 | 78 | 4 | 0.797 | Y | 351 | 101 | 10 |
|         | Tan et al.    | 2013 | Asian | PCR    | HB | CRC | 163 | 69 | 5 | 0.459 | Y | 169 | 60 | 8 |
|         | Wang et al.   | 2014 | Asian | PCR-RFLP | HB | BC | 297 | 162 | 42 | 0.004 | N | 212 | 102 | 32 |
|         | Wang et al.   | 2014 | Asian | PCR-RFLP | HB | BC | 297 | 162 | 42 | 0.004 | N | 46 | 25 | 0 |
|         | Wang et al.   | 2014 | Asian | PCR-RFLP | HB | BC | 297 | 162 | 42 | 0.004 | N | 30 | 20 | 7 |
|         | He et al.     | 2009 | Asian | PCR    | HB | HCC | 685 | 181 | 20 | 0.056 | Y | 149 | 52 | 1 |
|         | Han et al.    | 2015 | Asian | PCR-RFLP | HB | PC | 586 | 321 | 29 | 0.058 | Y | 508 | 356 | 72 |
|         | Umar et al.   | 2013 | Asian | PCR    | HB | ESCC | 149 | 141 | 21 | 0.100 | Y | 142 | 122 | 23 |
| rs3138053 | Lin et al.  | 2012 | Asian | TaqMan | HB | ORC | 438 | 78 | 4 | 0.797 | Y | 351 | 101 | 10 |
|         | Tan et al.    | 2013 | Asian | PCR    | HB | CRC | 163 | 69 | 5 | 0.459 | Y | 169 | 60 | 8 |
|         | Gao et al.    | 2014 | Asian | PCR    | PB | HCC | 336 | 48 | 40 | 0.000 | N | 173 | 21 | 19 |
|         | Spink et al.  | 2006 | Caucasian | PCR | PB | MM | 94 | 91 | 11 | 0.066 | Y | 64 | 77 | 16 |
|         | He et al.     | 2009 | Asian | PCR    | HB | HCC | 780 | 106 | 0 | 0.030 | Y | 164 | 30 | 0 |
|         | Han et al.    | 2015 | Asian | PCR-RFLP | HB | PC | 586 | 321 | 29 | 0.058 | Y | 508 | 356 | 72 |
|         | Zhang et al.  | 2014 | Asian | PCR    | HB | HCC | 1289 | 308 | 27 | 0.087 | Y | 214 | 38 | 1 |
|         | Cheng et al.  | 2013 | Asian | PCR    | HB | HCC | 438 | 78 | 4 | 0.797 | Y | 106 | 27 | 2 |
|         | Umar et al.   | 2013 | Asian | PCR    | PB | ESCC | 59 | 165 | 87 | 0.219 | Y | 71 | 140 | 79 |
|         | Gao et al.    | 2006 | Asian | PCR-RFLP | HB | CRC | 81 | 259 | 237 | 0.450 | Y | 126 | 109 | 64 |
|         | Gao et al.    | 2006 | Asian | PCR-RFLP | HB | CRC | 81 | 259 | 237 | 0.450 | Y | 126 | 109 | 64 |
|         | Gao et al.    | 2006 | Asian | PCR-RFLP | HB | CRC | 81 | 259 | 237 | 0.450 | Y | 126 | 109 | 64 |
|         | Gao et al.    | 2006 | Asian | PCR-RFLP | HB | CRC | 81 | 259 | 237 | 0.450 | Y | 126 | 109 | 64 |
|         | Gao et al.    | 2006 | Asian | PCR-RFLP | HB | CRC | 81 | 259 | 237 | 0.450 | Y | 126 | 109 | 64 |
|         | Gao et al.    | 2006 | Asian | PCR-RFLP | HB | CRC | 81 | 259 | 237 | 0.450 | Y | 126 | 109 | 64 |
|         | Zhang et al.  | 2014 | Caucasian | PCR-RFLP | HB | CRC | 74 | 221 | 143 | 0.466 | Y | 29 | 72 | 54 |
|         | Gao et al.    | 2014 | Asian | PCR    | HB | HCC | 248 | 794 | 561 | 0.231 | Y | 55 | 109 | 84 |
|         | Gao et al.    | 2014 | Asian | PCR    | HB | HCC | 248 | 794 | 561 | 0.231 | Y | 55 | 109 | 84 |
|         | Osborne et al. | 2005 | Caucasian | PCR | PB | HL | 8 | 22 | 20 | 0.64 | Y | 4 | 26 | 21 |
|         | Chang et al.  | 2009 | Caucasian | Taqman | PB | HL | 53 | 158 | 153 | 0.245 | Y | 92 | 215 | 156 |
|         | Han et al.    | 2015 | Asian | PCR-RFLP | HB | PC | 165 | 458 | 313 | 0.909 | Y | 173 | 442 | 321 |
|         | Song et al.   | 2011 | Caucasian | PCR-RFLP | PB | CRC | 212 | 531 | 262 | 0.06 | Y | 233 | 460 | 308 |

PCR – polymerase chain reaction; PCR-RFLP – polymerase chain reaction-restriction fragment length polymorphism; \( Y = P_{(\text{fixed})} > 0.05; \) \( N = P_{(\text{meta})} < 0.05; \) HCC – hepatocellular carcinoma; OC – ovarian cancer; BC – breast cancer; CRC – colorectal cancer; HL – Hodgkin lymphoma; PC – prostate cancer; ESCC – esophageal squamous cell carcinoma; MM – multiple myeloma; ORC – oral cancer; HB – hospital-based; PB – population-based.

Sensitivity analysis and publication bias risk

The sensitivity analyses were conducted by excluding each single case-control study in turn, and no separate study shows an influence on the pooled \( OR. \) Begg’s funnel plot and Egger’s test were performed to assess the risk of publication bias and no visual publication bias was shown (rs3138053: C vs. T: \( P = 0.181 \) for egger’s test; rs696: CC+CT vs. TT: \( P = 0.552 \) for
Egger’s test, Figure 3A; rs2233406: CC vs. CT+TT: P = 0.175 for Egger’s test, Figure 3B).

**Discussion**

The activation and translocation of NF-κB to the nucleus modulate the translation of the genes involved in inflammatory and immune activities, cell adhering, differentiating, growing, angiogenesis, and apoptosis through kinases, which leads to the phosphorylation, ubiquitination, and degradation of IκBs [37]. The p50 subunit, encoded by the NF-κB, has several common polymorphisms in the promoter region. The promoter sequence polymorphisms contribute to an increased expression of NF-κB messenger (m) RNA. NF-κB is important to cancer pathogenesis, preventing apoptosis and enhancing growth and survival by the upregulation of several genes [38]. Individual single-nucleotide polymorphisms (rs2233406, rs3138053, and rs696) in the NFKBIA gene may affect expression and function of the protein. Specifically, allelic differences in the NFKBIA promoter and 30UTR region may change IκBa expression and affect complex formation with NF-κB. In this way, cell growth and anti-apoptosis are regulated [39].

Li et al. [40] and Zou et al. [41] reported that genetic polymorphisms of the NFKBIA gene were associated with cancer.

### Table 2A. Results of meta-analysis for rs2233406 polymorphism in NFKBA and cancer susceptibility.

| Variables (rs2233406) | OR (95% CI) | OR (95% CI) | OR (95% CI) |
|-----------------------|-------------|-------------|-------------|
| **Case/ control**     | **C vs. T** | **CC vs. TT** | **CT vs. TT** |
| Total                 | 1.098 (0.944–1.277) | 1.387 (0.942–2.042) | 1.077 (0.931–1.246) |
| **Source of control** |             |             |             |
| HB                    |             |             |             |
| 3384/6930             | 1.112 (0.942–1.312) | 1.417 (0.914–2.198) | 1.094 (0.941–1.284) |
| **Cancer type**       |             |             |             |
| HCC                   |             |             |             |
| 588/3047              | 1.082 (0.851–1.375) | 1.038 (0.348–3.103) | 1.131 (0.789–1.622) |
| BC                    | 0.841 (0.581–1.215) | 0.390 (0.026–5.968) | 0.693 (0.673–2.221) |
| HWE                   |             |             |             |
| Y                     | 1.148 (0.967–1.362) | 1.535 (0.982–2.400) | 1.103 (0.924–1.318) |
| N                     | 0.952 (0.691–1.310) | 0.994 (0.398–2.484) | 0.624 (0.750–1.214) |

| **Case/ control**     | **CC+CT vs. TT** | **CC vs. CT+TT** |
| Total                 | 1.097 (0.937–1.283) | 1.390 (0.977–1.978) |
| **Source of control** |             |             |
| HB                    | 1.117 (0.944–1.323) | 1.409 (0.940–2.111) |
| **Cancer type**       |             |             |
| HCC                   | 1.115 (0.821–1.515) | 1.014 (0.324–3.175) |
| BC                    | 0.889 (0.695–1.138) | 0.396 (0.024–6.446) |
| HWE                   |             |             |
| Y                     | 1.137 (0.944–1.369) | 1.535 (1.027–2.296)* |
| N                     | 0.949 (0.758–1.188) | 1.009 (0.425–2.396) |

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License
Table 2B. Results of meta-analysis for rs3138053 polymorphism in NFKBA and cancer susceptibility.

| Variables (rs3138053) | Case/ control | C vs. T | CC vs. TT | TC vs. TT |
|------------------------|---------------|---------|-----------|-----------|
|                        | OR (95% CI)   | P       | I² (%)    | OR (95% CI) | P       | I² (%) |
| Total                  | 2595/5343     | 10.754  | (4.175–27.697)* | 0.000 97.8 | 1.683  | (0.979–2.891) | 0.023 34.8 | 1.178  | (0.954–1.455) | 0.012 39.9 |
| Source of control      |               |         |           |           |         |           |         |           |         |
| HB                     | 1972/3099     | 10.381  | (3.513–30.677)* | 0.000 97.4 | 2.652  | (1.810–3.886) | 0.767 0.0 | 1.335  | (1.075–1.657) | 0.093 24.7 |
| PB                     | 623/2244      | 11.377  | (1.472–87.963)* | 0.000 98.6 | 1.029  | (0.415–2.551) | 0.068 39.3 | 0.913  | (0.662–1.259) | 0.205 13.5 |
| Ethnicity              |               |         |           |           |         |           |         |           |         |
| Asian                  | 2438/5147     | 13.628  | (4.922–37.731) | 0.000 97.8 | 1.577  | (0.817–3.043) | 0.013 42.9 | 1.168  | (0.920–1.483) | 0.006 44.5 |
| Cancer type            |               |         |           |           |         |           |         |           |         |
| HCC                    | 590/3030      | 42.180  | (27.970–63.612)* | 0.007 63.8 | 0.718  | (0.070–7.340) | 0.077 46.2 | 1.206  | (0.706–2.062) | 0.007 63.7 |
| HWE                    |               |         |           |           |         |           |         |           |         |
| Y                      | 2382/4919     | 10.585  | (3.663–30.581) | 0.000 98.0 | 2.133  | (1.317–3.455)* | 0.217 8.5 | 1.216  | (0.975–1.518) | 0.012 40.1 |
| N                      | 213/424       | 12.036  | (8.430–17.184) | – – | 0.923  | (0.519–1.641) | – – | 0.850  | (0.493–1.465) | – – |
| Case/ control          |               |         |           |           |         |           |         |           |         |
| CC+TC vs. TT           |               |         |           |           |         |           |         |           |         |
| OR (95% CI)            |             | 1.209   | (0.964–1.517) | 0.002 48.9 | 1.632  | (1.001–2.660) | 0.055 26.3 |
| Source of control      |               |         |           |           |         |           |         |           |         |
| HB                     | 1972/3099     | 1.405   | (1.146–1.721)* | 0.114 21.4 | 2.460  | (1.686–3.590)* | 0.867 39.0 |
| PB                     | 623/2244      | 0.928   | (0.639–1.347) | 0.074 37.9 | 1.632  | (1.001–2.660) | 0.105 26.3 |
| Ethnicity              |               |         |           |           |         |           |         |           |         |
| Asian                  | 2438/5147     | 1.192   | (0.923–1.539) | 0.001 54.9 | 1.553  | (0.851–2.834) | 0.031 35.2 |
| Cancer type            |               |         |           |           |         |           |         |           |         |
| HCC                    | 590/3030      | 1.192   | (0.668–2.127) | 0.003 69.1 | 0.716  | (0.080–6.438) | 0.094 41.3 |
| HWE                    |               |         |           |           |         |           |         |           |         |
| Y                      | 2382/4919     | 1.260   | (0.992–1.601) | 0.003 49.3 | 2.063  | (1.350–3.154)* | 0.296 3.3 |
| N                      | 213/424       | 0.883   | (0.582–1.339) | – – | 0.940  | (0.530–1.667) | – – |
### Table 2C. Results of meta-analysis for rs696 polymorphism in \(NFKBIA\) and cancer susceptibility.

| Variables (rs696) | Case/control | C vs. T | OR (95% CI) | \(P^a\) | I² (%) | CC vs. TT | OR (95% CI) | \(P^a\) | I² (%) | CT vs. TT | OR (95% CI) | \(P^a\) | I² (%) |
|------------------|--------------|---------|-------------|---------|--------|----------|-------------|---------|--------|----------|-------------|---------|--------|
| **Total**        | 3556/5705    |         | 0.952 (0.894–1.014) | 0.121   | 13.8   | 0.891 (0.783–1.013) | 0.194   | 79.5   | 0.884 (0.738–1.058) | 0.044   | 24.6   |
| **Ethnicity**    |              |         |             |         |        |          |             |         |        |          |             |         |        |
| Caucasian        | 1670/1857    |         | 0.971 (0.882–1.069) | 0.034   | 0.0    | 0.930 (0.766–1.128) | 0.055   | 36.5   | 0.809 (0.676–0.969) | 0.459   | 0.0    |
| Asian            | 1886/3848    |         | 0.939 (0.863–1.021) | 0.431   | 42.6   | 0.861 (0.725–1.023) | 0.527   | 0.0    | 0.921 (0.691–1.227) | 0.015   | 45.8   |
| **Source of control** |            |         |             |         |        |          |             |         |        |          |             |         |        |
| PB               | 2018/2151    |         | 0.963 (0.882–1.051) | 0.047   | 34.2   | 0.906 (0.759–1.081) | 0.080   | 27.1   | 0.908 (0.687–1.200) | 0.050   | 33.4   |
| HB               | 1538/3554    |         | 0.941 (0.858–1.031) | 0.397   | 0.0    | 0.875 (0.726–1.054) | 0.439   | 0.0    | 0.868 (0.656–1.148) | 0.093   | 28.3   |
| **Cancer type**  |              |         |             |         |        |          |             |         |        |          |             |         |        |
| HL               | 514/414      |         | 0.887 (0.656–0.956)* | 0.116   | 34.8   | 0.658 (0.448–0.965)* | 0.076   | 46.6   | 1.126 (0.408–3.111) | 0.118   | 34.8   |
| CRC              | 1355/2020    |         | 1.003 (0.907–1.110) | 0.269   | 5.7    | 1.014 (0.825–1.2480) | 0.702   | 0.0    | 0.901 (0.673–1.206) | 0.184   | 16.7   |

**Case/control CC+CT vs. TT**

| Case/control | OR (95% CI) | \(P^a\) | I² (%) | OR (95% CI) | \(P^a\) | I² (%) |
|--------------|-------------|---------|--------|-------------|---------|--------|
| **Total**    | 0.879 (0.787–0.982)* | 0.107   | 15.3   | 0.946 (0.811–1.103) | 0.025   | 29.5   |
| **Ethnicity** |              |         |        |             |         |        |
| Caucasian    | 0.851 (0.719–1.007) | 0.304   | 3.1    | 1.002 (0.718–1.399) | 0.010   | 53.7   |
| Asian        | 0.901 (0.778–1.044) | 0.054   | 32.5   | 0.923 (0.798–1.068) | 0.306   | 2.9    |
| **Source of control** |            |         |        |             |         |        |
| PB           | 0.945 (0.765–1.028) | 0.075   | 28.1   | 0.945 (0.718–1.243) | 0.016   | 45.0   |
| HB           | 0.870 (0.736–1.028) | 0.205   | 11.9   | 0.942 (0.781–1.136) | 0.165   | 16.9   |
| **Cancer type** |            |         |        |             |         |        |
| HL           | 0.758 (0.534–1.077) | 0.080   | 45.3   | 0.734 (0.562–0.958)* | 0.347   | 0.0    |
| CRC          | 0.908 (0.760–1.086) | 0.726   | 0.0    | 0.995 (0.680–1.456) | 0.009   | 62.4   |

\(I^2\) – 0–25, means no heterogeneity; 25–50, means modest heterogeneity; >50, means high heterogeneity; HWE – Hardy-Weinberg equilibrium; Y – polymorphisms conformed to HWE in the control group; N – polymorphisms did not conform to HWE in the control group; \(P\) – \(P\) value of Q test for heterogeneity test; * means statistically significant (\(P<0.05\)). The source of control, HB – hospital-based; PB – population-based; HCC – hepatocellular carcinoma; HL – Hodgkin lymphoma; CRC – colorectal cancer; BC – breast cancer.
Table 3. Methodological quality of the included studies according to the Newcastle-Ottawa Scale.

| rs2233406 | Lu et al. | Asian | * | * | NA | * | ** | * | * | * | * |
|-----------|-----------|-------|---|---|----|---|----|---|---|---|---|
| Zhang et al. | Asian | * | * | NA | * | ** | * | * | * | * |
| Cheng et al. | Asian | * | * | NA | * | ** | * | * | * | * |
| Lin et al. | Asian | * | * | NA | * | ** | * | * | * | * |
| Tan et al. | Asian | * | * | NA | * | ** | * | * | * | * |
| Wang et al. | Asian | * | * | NA | * | ** | * | * | * | * |
| Wang et al. | Asian | * | * | NA | * | ** | * | * | * | * |
| He et al. | Asian | * | * | NA | * | ** | * | * | * | * |
| Han et al. | Asian | * | * | NA | * | ** | * | * | * | * |
| Umar et al. | Asian | * | * | * | * | ** | * | * | * | * |
| rs3138053 | Lin et al. | Asian | * | * | NA | * | ** | * | * | * | * |
| Zhang et al. | Asian | * | * | NA | * | ** | * | * | * | * |
| Han et al. | Asian | * | * | NA | * | ** | * | * | * | * |
| Gao et al. | Asian | * | * | * | * | ** | * | * | * | * |
| Spink et al. | Caucasian | * | * | * | NA | ** | * | * | * | * |
| He et al. | Asian | * | * | NA | * | ** | * | * | * | * |
| Han et al. | Asian | * | * | NA | * | ** | * | * | * | * |
| Zhang et al. | Asian | * | * | * | * | ** | * | * | * | * |
| Cheng et al. | Asian | * | * | NA | * | ** | * | * | * | * |
| rs696 | Umar et al. | Asian | * | * | * | * | ** | * | * | * | * |
| Gao et al. | Asian | * | * | NA | * | ** | * | * | * | * |
| Gao et al. | Caucasian | * | * | NA | * | ** | * | * | * | * |
| Zhang et al. | Asian | * | * | NA | * | ** | * | * | * | * |
| Gao et al. | Asian | * | * | * | * | ** | * | * | * | * |
| Osborne et al. | Caucasian | * | * | * | NA | ** | * | * | * | * |
| Chang et al. | Caucasian | * | * | * | * | ** | * | * | * | * |
| Han et al. | Asian | * | * | NA | * | ** | * | * | * | * |
| Song et al. | Caucasian | * | * | * | * | ** | * | * | * | * |

This table identifies ‘high’ quality choices with a ‘star’. A study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum of two stars can be given for Comparability. *, Yes; NA – not applicable. (http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm).
### Figure 2A. Meta-analysis of the association between NFKBIA rs3138053 polymorphism and overall cancer susceptibility (C vs. T).

| Study ID          | OR (95% CI) | % weight |
|-------------------|-------------|----------|
| Spink et al. (2006) | 2.05 (1.51, 2.79) | 12.50    |
| He et al. (2009)   | 41.05 (29.58, 56.97) | 12.48    |
| Lin et al. (2012)  | 7.87 (5.75, 10.52)  | 12.51    |
| Tan et al. (2013)  | 4.72 (3.35, 6.65)   | 12.46    |
| Cheng et al. (2013) | 29.17 (20.02, 42.50) | 12.42    |
| Zhang et al. (2014) | 59.49 (45.84, 77.21) | 12.55    |
| Gao et al. (2014)  | 12.04 (8.43, 17.18)  | 12.45    |
| Han et al. (2015)  | 2.81 (2.41, 3.28)    | 12.63    |
| Overall (I-squared=98.9%, p=0.000) | 10.75 (4.18, 27.70) | 100.00   |

*Note: Weights are from random effects analysis.*

### Figure 2B. Meta-analysis of the association between NFKBIA rs696 polymorphism and overall cancer susceptibility (CC+CT vs. TT).

| Study ID          | OR (95% CI) | % weight |
|-------------------|-------------|----------|
| Osborne et al. (2005) | 2.24 (0.63, 7.97) | 0.50     |
| Gao et al. (2006)   | 1.09 (0.68, 1.75)  | 5.01     |
| Gao et al. (2006)   | 0.88 (0.55, 1.42)  | 5.36     |
| Chang et al. (2006) | 0.69 (0.47, 0.99)  | 10.42    |
| Song et al. (2011)  | 0.88 (0.71, 1.09)  | 27.75    |
| Umar et al. (2013)  | 0.72 (0.49, 1.07)  | 8.97     |
| Zhang et al. (2014) | 0.64 (0.46, 0.89)  | 12.13    |
| Gao et al. (2014)   | 1.25 (0.88, 1.87)  | 8.40     |
| Han et al. (2015)   | 0.94 (0.75, 1.19)  | 21.46    |
| Overall (I-squared=59.1%, p=0.107) | 0.88 (0.79, 0.98) | 100.00   |

### Figure 2C. Subgroup analysis of the association between NFKBIA polymorphisms and overall cancer risk by HWE (Hardy-Weinberg equilibrium).

| Study ID          | OR (95% CI) | % weight |
|-------------------|-------------|----------|
| Wang et al. (2014) | 0.08 (0.00, 1.24) | 1.49     |
| Wang et al. (2014) | 1.11 (0.69, 1.80) | 16.09    |
| Wang et al. (2014) | 1.53 (0.65, 3.59) | 9.83     |
| Subtotal (I-squared=57.7%, p=0.094) | 1.01 (0.42, 2.40) | 27.41    |
| N                 |             |          |
| He et al. (2009)   | 0.22 (0.03, 1.61) | 2.71     |
| Lin et al. (2012)  | 2.85 (0.89, 9.16) | 6.54     |
| Cheng et al. (2013) | 1.94 (0.35, 10.70) | 3.60     |
| Tan et al. (2013)  | 1.62 (0.52, 5.03) | 6.83     |
| Umar et al. (2013) | 1.19 (0.64, 2.20) | 13.55    |
| Zhang et al. (2014) | 1.41 (0.58, 3.44) | 9.31     |
| Han et al. (2015)  | 2.61 (1.68, 4.05) | 16.92    |
| Lu et al. (2015)   | 1.05 (0.56, 1.99) | 13.14    |
| Subtotal (I-squared=42.0%, p=0.099) | 1.54 (1.03, 2.30) | 72.59    |
| Overall (I-squared=46.7%, p=0.043) | 1.39 (0.98, 1.98) | 100.00   |

*Note: Weights are from random effects analysis.*
susceptibility and severity in sporadic colorectal cancer and oral cancer. Klein et al. [42] proved that the polymorphism of \( \text{NFKBIA} \) was linked to Crohn’s disease. Other studies also drew similar conclusions in breast [9], prostate [13], and stomach [14] cancers. However, results from studies in various geographic areas were not consistent. To the best of our knowledge, this is the first meta-analysis to assess the relationship between these 3 polymorphisms (rs2233406, rs3138053, and rs696) of \( \text{NFKBIA} \) gene and overall cancer susceptibility. Our analysis validated that individuals with the variant allele (rs3138053) appear to have increased susceptibility to cancer. Interestingly, we found a contrary effect of variant allele (rs696), which seems to be associated with decreased susceptibility to cancer. In the subgroup analysis by cancer type, significantly decreased susceptibility of Hodgkin lymphoma with rs696 polymorphism was observed, whereas no significant association was found among studies of colorectal cancer.

The heterogeneity test in the present study showed that there was no evident heterogeneity in terms of the 3 polymorphisms for all cancer types between the studies. Additionally, various cancer categories did not contribute to the overall heterogeneity in association with the polymorphisms, suggesting that our present combined analyses were unbiased, regardless of cancer types. Despite the obvious advantages of our meta-analysis containing large sample sizes, some limitations of this study should be mentioned. The complex factors such as age, sex, and region may bring some bias. Studies reported in other languages may bias the present results because the negative findings are usually difficult to be included. Therefore, further study is needed to evaluate the independent and combined effect of these polymorphisms.

**Conclusions**

In conclusion, this meta-analysis indicated that the rs3138053 polymorphism of \( \text{NFKBIA} \) gene is a candidate for susceptibility to overall cancers, especially in HCC cancer, while the rs696 plays a protective role against cancers, especially in Hodgkin lymphoma patients and in Caucasians. Moreover, because of the limitations described above, well-designed studies considering gene-gene and gene-environment effects should be conducted to confirm these relationships.

**Conflict of interest statement**

None.

**References:**

1. Domingo-Domenech J, Oliva C, Rovira A et al: Interleukin 6, a nuclear factor-κappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res, 2006; 12(18): 5578–86

2. Ahn KS, Sethi G, Aggarwal BB: Nuclear factor-kappa B: from clone to clinic. Curr Mol Med, 2007; 7(7): 619–37

3. Naugler WE, Karin M: NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev, 2008, 18(1): 19–26
4. Lind DS HS, Malaty J, Rekkas S et al: Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery. 2001; 130: 363–69
5. Oltulu YM, Coskunpınar E, Özkcan G et al: Investigation of NF-kappaB1 and NF-kappaBIA gene polymorphism in non-small cell lung cancer. Biomed Res Int, 2014; 2014: 530381
6. Yang JI, Cho LY, Ko KP et al: Interaction effects between genes involved in the AKT signaling pathway and phytoestrogens in gastric carcinogenesis: a nested case-control study from the Korean Multi-Center Cancer Cohort. Mol Nutr Food Res, 2012; 56(11): 1617–26
7. Shielis MS, Engels EA, Shi J et al: Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk. Cancer, 2012; 118(22): 5630–36
8. Huang D, Yang L, Liu Y et al: Functional polymorphisms in NFkappaB1/ IkappaBalpha predict risks of chronic obstructive pulmonary disease and lung cancer in Chinese. Hum Genet, 2013; 132(4): 451–60
9. Curran JE, Weinstein SR, Griffiths LR: Polymorphic variants of NFKB1 and its inhibitory protein NFKBIA, and their involvement in sporadic breast cancer. Cancer Lett, 2002; 188(1–2): 103–7
10. Lewander A, Armban G, Sun XF: Polymorphism in the promoter region of the NFKBIA gene is rare in Swedish and Chinese colorectal cancer patients and controls. Mol Med Rep, 2010; 3(1): 69–74
11. White KL, Vierkant RA, Phelan CM et al: Polymorphisms in NF-kappab inhibitors and risk of epithelial ovarian cancer. BMC Cancer, 2009; 9: 170
12. Shafi'i MSM SS, Mustapha MA: The genetic variation A>G at 3’ UTR of nucleoside diphosphate kinase A gene is associated with Hodgkin lymphoma. Int J Cancer, 2005; 116(4): 646–51
13. Gao J, Xu HL, Gao S et al: Genetic polymorphism of NFkappaB1 and NFkappaBIA genes and liver cancer risk: a nested case-control study in Shanghai, China. BMJ Open, 2014; 4(2): e004427
14. Han X, Zhang J, Yao N et al: Polymorphisms in NFkappaB1 and NFkappaBIA Genes Modulate the Risk of Developing Prostate Cancer among Han Chinese. Med Sci Monit, 2015; 21: 1705–17
15. He Y, Zhang H, Yin J et al: IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. Carcinogenesis, 2009; 30(11): 1916–22
16. Lin CW, Hsieh YS, Hsin CH et al: Effects of NFkappaB1 and NFkappaBIA gene polymorphisms on susceptibility to environmental factors and the clinicopathologic development of oral cancer. PloS One, 2012; 7(4): e35078
17. Lu ZH, Gu XJ, Shi KZ et al: Association between genetic polymorphisms of inflammatory response genes and the risk of ovarian cancer. J Biosci Med Assoc, 2015 [Epub ahead of print]
18. Osborne J, Lake A, Alexander FE et al: Germine mutations and polymorphisms in the NFKBIA gene in Hodgkin lymphoma. Int J Cancer, 2005; 116(4): 646–51
19. Song S, Chen D, Lu J et al: NFkappaB1 and NFkappaBIA polymorphisms are associated with increased risk for sporadic colorectal cancer in a southern Chinese population. PloS One, 2011; 6(6): e21776
20. Spink CF, Gray LC, Davies FE et al: haplotype structure across the I kappa B alpha gene (NFKBIA) and association with multiple myeloma. Cancer Lett, 2007; 246(1–2): 92–99
21. Tan SC, Suzairi MS, Alizat AA, Aminuddin MM et al: Gender-specific association of NFKBIA promoter polymorphisms with the risk of sporadic colorectal cancer. Med Oncol, 2013; 30(4): 693
22. Umar M, Upadhaya R, Kumar S et al: Association of common polymorphisms in TNFA, NFkB1 and NFkappaBIA with risk and prognosis of esophageal squamous cell carcinoma. PloS One, 2013; 8(12): e81999
23. Wang Z, Liu Q, Sun W et al: Genetic polymorphisms in inflammatory response genes and their associations with breast cancer risk. Croat Med J, 2014; 55(6): 638–46
24. Zhang Q: Effect of functional nuclear factor kappab gene polymorphisms on hepatitis B virus persistence and their interactions with viral mutations on the risk of hepatocellular carcinoma. Annals of Oncology Advance Access, 2014
25. Sun Z, Andersson R: NF-kappab activation and inhibition: a review. Shock, 2002; 18(2): 99–106
26. Charbonneau B, Block MS, Bamlet WR et al: Risk of ovarian cancer and the NF-kappab pathway: genetic association with IL1A and TNFSF10. Cancer Res, 2014; 74(3): 852–61
27. Wang S, Zhang M, Zeng Z et al: ikappaBalpha polymorphisms were associated with increased risk of gastric cancer in a southern Chinese population: a case-control study. Life Sci, 2011; 88(17–18): 792–97
28. Li KR, Hung YH, Lin CH et al: Inhibitor IkappaBalpha promoter functional polymorphisms in patients with rheumatoid arthritis. J Clin Immunol, 2010; 30(5): 676–80
29. Zou YF, Feng XL, Tao JH, Ding N: Association between NFKB1-94ins/deletion polymorphism and risk of esophageal squamous cell carcinoma. PloS One, 2013; 8(12): e81999